Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Aug 26

PMID 36010836

Authors

Xingliang Fang

Huanrong Lan

Ketao Jin

Daojun Gong

Jun Qian

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy has received more and more attention from cancer researchers over the past few decades. Various methods such as cell therapy, immune checkpoint blockers, and cancer vaccines alone or in combination therapies have achieved relatively satisfactory results in cancer therapy. Among these immunotherapy-based methods, cancer vaccines alone have not yet had the necessary efficacy in the clinic. Therefore, nanomaterials have increased the efficacy and ef-fectiveness of cancer vaccines by increasing their half-life and durability, promoting tumor mi-croenvironment (TME) reprogramming, and enhancing their anti-tumor immunity with minimal toxicity. In this review, according to the latest studies, the structure and different types of nanovaccines, the mechanisms of these vaccines in cancer treatment, as well as the advantages and disadvantages of these nanovaccines are discussed.

Citing Articles

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.

Chen C, Xu Y, Meng H, Bao H, Hu Y, Li C Nanomaterials (Basel). 2025; 15(2).

PMID: 39852737 PMC: 11767563. DOI: 10.3390/nano15020122.

Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.

Kumar N, Mangla M Cancer Chemother Pharmacol. 2025; 95(1):18.

PMID: 39754614 DOI: 10.1007/s00280-024-04747-4.

New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review).

Bhaliya K, Anwer M, Munn A, Wei M Mol Clin Oncol. 2024; 22(1):4.

PMID: 39563999 PMC: 11574705. DOI: 10.3892/mco.2024.2799.

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice.

Kim J, Zhu W, Dong C, Wei L, Ma Y, Denning T Nanoscale Horiz. 2024; 9(11):2016-2030.

PMID: 39240547 PMC: 11493517. DOI: 10.1039/d4nh00287c.

References

Woo S, Fuertes M, Corrales L, Spranger S, Furdyna M, Leung M . STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014; 41(5):830-42. PMC: 4384884. DOI: 10.1016/j.immuni.2014.10.017. View

Mancini F, Rossi O, Necchi F, Micoli F . OMV Vaccines and the Role of TLR Agonists in Immune Response. Int J Mol Sci. 2020; 21(12). PMC: 7352230. DOI: 10.3390/ijms21124416. View

Kyi C, Postow M . Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016; 8(7):821-37. PMC: 5619130. DOI: 10.2217/imt-2016-0002. View

Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R . Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Lett. 2021; 21(5):2224-2231. DOI: 10.1021/acs.nanolett.0c05039. View

van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz E . Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002; 188:51-64. DOI: 10.1034/j.1600-065x.2002.18806.x. View

Basle E, Joubert N, Pucheault M . Protein chemical modification on endogenous amino acids. Chem Biol. 2010; 17(3):213-27. DOI: 10.1016/j.chembiol.2010.02.008. View

Tian L, Chen Q, Yi X, Wang G, Chen J, Ning P . Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer. Theranostics. 2017; 7(3):614-623. PMC: 5327637. DOI: 10.7150/thno.17381. View

Meng J, Duan J, Kong H, Li L, Wang C, Xie S . Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small. 2008; 4(9):1364-70. DOI: 10.1002/smll.200701059. View

10.

Pecot C, Calin G, Coleman R, Lopez-Berestein G, Sood A . RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2010; 11(1):59-67. PMC: 3199132. DOI: 10.1038/nrc2966. View

11.

Rodriguez-Pinto D . B cells as antigen presenting cells. Cell Immunol. 2006; 238(2):67-75. DOI: 10.1016/j.cellimm.2006.02.005. View

12.

Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley A, McArdle S . Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Front Immunol. 2021; 11:615240. PMC: 7927599. DOI: 10.3389/fimmu.2020.615240. View

13.

Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J . Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol. 1990; 20(9):1893-7. DOI: 10.1002/eji.1830200904. View

14.

Zhu G, Zhang F, Ni Q, Niu G, Chen X . Efficient Nanovaccine Delivery in Cancer Immunotherapy. ACS Nano. 2017; 11(3):2387-2392. DOI: 10.1021/acsnano.7b00978. View

15.

Vangasseri D, Cui Z, Chen W, Hokey D, Falo Jr L, Huang L . Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol. 2006; 23(5):385-95. DOI: 10.1080/09687860600790537. View

16.

Tam H, Melo M, Kang M, Pelet J, Ruda V, Foley M . Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A. 2016; 113(43):E6639-E6648. PMC: 5086995. DOI: 10.1073/pnas.1606050113. View

17.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

18.

Liu X, Su Q, Song H, Shi X, Zhang Y, Zhang C . PolyTLR7/8a-conjugated, antigen-trapping gold nanorods elicit anticancer immunity against abscopal tumors by photothermal therapy-induced in situ vaccination. Biomaterials. 2021; 275:120921. DOI: 10.1016/j.biomaterials.2021.120921. View

19.

Li L, Goedegebuure S, Gillanders W . Cancer vaccines: shared tumor antigens return to the spotlight. Signal Transduct Target Ther. 2020; 5(1):251. PMC: 7599325. DOI: 10.1038/s41392-020-00364-8. View

20.

Xiong X, Zhao J, Pan J, Liu C, Guo X, Zhou S . Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy. Nano Lett. 2021; 21(19):8418-8425. DOI: 10.1021/acs.nanolett.1c03004. View